Drug Profile
Research programme: anti-OX40 agonistic antibodies - Iovance Biotherapeutics
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Iovance Biotherapeutics
- Class Antibodies
- Mechanism of Action OX40 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Unspecified in USA
- 12 Mar 2018 Preclinical trials in Undefined indication in USA (unspecified route)
- 12 Mar 2018 Pharmacodynamics data from a early research in undisclosed indication released by Iovance Biotherapeutics